a Department of Urology , University Hospitals Leuven , Leuven , Belgium.
b Faculty of Health, Education, Medicine and Social Care, Medical Technology Research Centre , Anglia Ruskin University , Chelmsford , UK.
Expert Opin Emerg Drugs. 2019 Mar;24(1):1-4. doi: 10.1080/14728214.2019.1591370. Epub 2019 Mar 19.
Finding novel medical treatment for Peyronie's disease (PD) has suffered from similar limitations and difficulties as other fibrotic diseases.Areas covered: Underlying fibrosis, there is a vastly complex intertwining of several pathways. Focusing on a single target during antifibrotic drug development has not led to the development of many efficacious drugs, especially in PD. Inhibiting one cog in this large machinery usually leads to activation of compensatory mechanisms.Expert opinion: Novel strategies in drug discovery such as phenotypical drug screening and gene expression profiling technologies could provide a solution for this impasse.
寻找治疗 Peyronie 病 (PD) 的新方法遇到了与其他纤维化疾病类似的限制和困难。
在纤维化的潜在机制下，有几个途径错综复杂地交织在一起。在抗纤维化药物开发过程中，专注于单一靶点并未导致许多有效的药物开发，尤其是在 PD 中。抑制这一大机器中的一个齿轮通常会导致代偿机制的激活。
药物发现的新策略，如表型药物筛选和基因表达谱技术，可能为这一困境提供解决方案。
